Viewing nowPregabalin 150 mg Capsule
Pregabalin 150mg
Hard capsule · Prescription medication
Bionex Co., Ltd.

MFDS item code 201109286 · Approved 2011.10.31 · Insurance code 643103430
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, treatment of fibromyalgia
This medication is used in adults for the treatment of peripheral and central neuropathic pain. It is also used as an adjunct for partial seizures in epilepsy patients, regardless of the presence of secondary generalized symptoms. Additionally, it is effective in alleviating symptoms of fibromyalgia. It helps improve symptoms of various neurological diseases.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys unchanged after passing through the systemic circulation. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For females, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age and adolescent patients aged 12 ~17 years because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so mood changes or symptoms of depression should be closely monitored during treatment. Patients with allergies to any ingredient in this medication or certain genetic conditions such as lactose intolerance should not take it. Diabetic patients may experience impacts on blood sugar control due to weight gain after taking this medication, so adjustments to antidiabetic medication dosages may be necessary. If serious allergic reactions such as angioedema occur, the medication should be immediately discontinued, and medical consultation should be sought. Elderly patients are at increased risk of falls due to dizziness or drowsiness that may occur while taking this medication. Blurred vision or other visual changes may occur, and if symptoms persist, discontinuation of the medication should be considered. Discontinuing this medication suddenly may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it should be tapered off gradually under a physician's guidance. Due to the risk of drug abuse, patients with a history of mental illness or substance abuse should take this medication with extra caution. Patients with impaired kidney function may require dose adjustments, and patients with heart disease should be monitored as well. When used in combination with central nervous system depressants such as opioids, there is a risk of respiratory depression, so care should be taken when taken together. Pregnant women should avoid this medication due to the risk of fetal malformation in early pregnancy, and women of childbearing potential should use effective contraception. Breastfeeding mothers should avoid this medication as it can be transmitted through breast milk. Caution is advised when engaging in hazardous activities such as driving or operating machinery due to the potential for dizziness or drowsiness. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatment like hemodialysis may be required. This medication must be stored out of reach of children and should not be transferred to other containers. If serious adverse reactions, such as skin rashes, fever, or breathing difficulties occur, immediate discontinuation and medical advice should be sought.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, swelling around the mouth, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, withdrawal symptoms, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, sensitivity, euphoria, decreased libido, depersonalization, sexual dysfunction, restlessness, mood swings, emotional downregulation, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, loss of impulse control, apathy, ataxia, abnormal coordination, balance disorders, amnesia, attention disorders, memory disorders, tremors, dysarthria, sensory abnormalities, sensory reduction, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myoclonus, decreased reflexes, abnormal movement, psychomotor agitation, position-related dizziness, hypersensitivity, burning sensation, action tremors, syncope, confusion, decreased motor function, olfactory disturbances, loss of taste, writing difficulties, blurred vision, diplopia, indirect field loss, visual disturbances, visual field defects, photophobia, dry eyes, conjunctival edema, decreased vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, changes in depth perception during shaking, strabismus, brightness perception, vertigo, auditory hypersensitivity, first-degree block, tachycardia, bradycardia, tachyarrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, abdominal bloating, excessive salivation, gastroesophageal reflux disease, oral sensory decrease, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, throat pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, swelling, gait abnormalities, falls, feeling drunk, sensory abnormalities, fatigue, tightness in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, elevated alanine aminotransferase, increased serum creatine phosphokinase, elevated aspartate aminotransferase, increased blood sugar, decreased platelet count, reduced serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorder, drowsiness, state of confusion, depression, agitation, restlessness, worsened seizures, sleep disorders, blood in stools, tinnitus
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is important to store it at room temperature between 15 to 30 degrees Celsius to maintain its effectiveness.
A hard capsule with a white or light yellow powder inside, with a white upper and lower part.
100 capsules/bottle, 30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Bionex Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.